1. Home
  2. LSH vs IGC Comparison

LSH vs IGC Comparison

Compare LSH & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSH
  • IGC
  • Stock Information
  • Founded
  • LSH 2018
  • IGC 2005
  • Country
  • LSH United States
  • IGC United States
  • Employees
  • LSH N/A
  • IGC N/A
  • Industry
  • LSH
  • IGC Biotechnology: Pharmaceutical Preparations
  • Sector
  • LSH
  • IGC Health Care
  • Exchange
  • LSH NYSE
  • IGC Nasdaq
  • Market Cap
  • LSH 28.6M
  • IGC 26.9M
  • IPO Year
  • LSH 2024
  • IGC N/A
  • Fundamental
  • Price
  • LSH $2.54
  • IGC $0.35
  • Analyst Decision
  • LSH
  • IGC Strong Buy
  • Analyst Count
  • LSH 0
  • IGC 2
  • Target Price
  • LSH N/A
  • IGC $3.63
  • AVG Volume (30 Days)
  • LSH 32.4K
  • IGC 222.5K
  • Earning Date
  • LSH 11-15-2024
  • IGC 11-12-2024
  • Dividend Yield
  • LSH N/A
  • IGC N/A
  • EPS Growth
  • LSH N/A
  • IGC N/A
  • EPS
  • LSH N/A
  • IGC N/A
  • Revenue
  • LSH $18,248,233.00
  • IGC $1,183,000.00
  • Revenue This Year
  • LSH N/A
  • IGC N/A
  • Revenue Next Year
  • LSH N/A
  • IGC $13.57
  • P/E Ratio
  • LSH N/A
  • IGC N/A
  • Revenue Growth
  • LSH 28.38
  • IGC N/A
  • 52 Week Low
  • LSH $2.10
  • IGC $0.25
  • 52 Week High
  • LSH $5.37
  • IGC $0.91
  • Technical
  • Relative Strength Index (RSI)
  • LSH N/A
  • IGC 42.76
  • Support Level
  • LSH N/A
  • IGC $0.33
  • Resistance Level
  • LSH N/A
  • IGC $0.42
  • Average True Range (ATR)
  • LSH 0.00
  • IGC 0.02
  • MACD
  • LSH 0.00
  • IGC -0.00
  • Stochastic Oscillator
  • LSH 0.00
  • IGC 32.14

About LSH LAKESIDE HOLDING LTD

Lakeside Holding Ltd i a U.S.-based integrated cross-border supply chain solution provider with a strategic focus on the Asian market including China and South Korea. It provides customized cross-border ocean freight solutions and airfreight solutions in the U.S, including (i) cross-border freight consolidation and forwarding services, (ii) customs clearance services, (iii) warehousing and distribution services and (iv) U.S. domestic ground transportation services.

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Share on Social Networks: